Search
VB2-011
go.drugbank.com/drugs/DB05411ExperimentalVB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma. … This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG).
Inonotus obliquus fruiting body
go.drugbank.com/drugs/DB14332ApprovedInonotus obliquus fruiting body is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Atractylodes lancea root oil
go.drugbank.com/drugs/DB14338ApprovedAtractylodes lancea root oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: OHUI Sun Science Sun Block EX plus Beige, O Hui White Extreme Blemish BalmLumefantrine co-artemether
go.drugbank.com/drugs/DB13085ApprovedInvestigationalWithdrawnUnlike artemether, lumefantrine has a slower onset of action, resulting in clearance of residual parasites and a decrease in recrudescence rate. … Lumefantrine Co-Artemether is a tablet formulation of artemether and lumefantrine, a well-tolerated, fast-acting and effective blood schizontocidal drug that serves primarily in the treatment of uncomplicated
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIbopamine
go.drugbank.com/drugs/DB13316ExperimentalCategories: Compounds used in a research, industrial, or household settingBG-777
go.drugbank.com/drugs/DB05839ExperimentalBG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.
Teverelix
go.drugbank.com/drugs/DB05624InvestigationalA synthetic decapeptide, water-soluble Gonadotropin-releasing hormone antagonist. It has reached phase II clinical trials.
Avdoralimab
go.drugbank.com/drugs/DB16392InvestigationalAvdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
LX1031
go.drugbank.com/drugs/DB05199InvestigationalLX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system … LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders.
MBT-0312
go.drugbank.com/drugs/DB05880ExperimentalMediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.